Insulin Delivery Devices Market by Type (Insulin Pens (Reusable, Disposable), Insulin Pumps (External/Tethered, Patch), Pen Needles (Standard, Safety), Insulin Syringes) and End User (Patients/Homecare, Hospitals & Clinics) - Global Forecast to 2021
出 版 商：MarketsandMarkets
出版日期：2017/04/24
頁 數：151頁
文件格式：PDF
價 格：
USD 5,650 (Single-User License)
USD 6,650 (Multi-User License)
USD 8,150 (Global-User License)
USD 6,650 (Multi-User License)
USD 8,150 (Global-User License)
The insulin delivery devices market is projected to reach USD 17.85 billion by 2021 from USD 11.54 billion in 2016, growing at a CAGR of 9.1% in the next five years (2016 to 2021).
Favorable reimbursement scenario and strong government support in selected countries, technological advancements in insulin delivery devices, growing diabetic population, and rising awareness about insulin delivery devices are the major factors driving the growth of this market. However, needle anxiety, emergence of oral drug delivery methods, and the growing trend of reuse of pen needles and infusion sets are the major factors restraining the growth of this market. Furthermore, increasing research and development activities and increasing diabetes-related health expenditure in emerging countries are likely to offer significant growth opportunities for players operating in the market.
The global insulin delivery devices market is segmented on the basis of type, end user, and region. In 2016, North America accounted for the largest share of the market, followed by Europe, Asia-Pacific, and RoW. The Asia-Pacific region is projected to have the highest growth rate in the forecast period. Factors such as rising prevalence of diabetes, high adoption of insulin pens, and government initiatives in Singapore are expected to support the growth of the Asia-Pacific insulin delivery devices market.
The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (product launches, collaborations, agreements, partnerships, alliances, grants, joint ventures, acquisitions, and expansions) to increase their market shares and establish a strong foothold in the global market.
In-depth interviews were conducted with CEOs, Sales and Marketing Directors, other innovation and technology directors, and executives from various key organizations operating in the insulin delivery devices market.
By Company Type: Tier 1: 70%, Tier 2: 22%, Tier 3: 8%
By Designation: Director Level: 65%, C-level: 25%, Others: 10%
By Region: North America: 55%, Europe: 20%, APAC: 20%, RoW: 5%
Key players in the global insulin delivery devices market include Becton, Dickinson and Company (U.S.), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Medtronic plc (Ireland), Animas Corporation (U.S.), Tandem Diabetes Care, Inc. (U.S.), Sanofi (France), Biocon Ltd. (India), Eli Lilly and Company (U.S.), and Insulet Corporation (U.S.).
?
Research Coverage:
This report studies the insulin delivery devices market based on type, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one, or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on the types of insulin delivery devices offered by top players in the insulin delivery devices market
‧ Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the insulin delivery devices market
‧ Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for insulin delivery devices across regions
‧ Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the insulin delivery devices market
‧ Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the insulin delivery devices market
Favorable reimbursement scenario and strong government support in selected countries, technological advancements in insulin delivery devices, growing diabetic population, and rising awareness about insulin delivery devices are the major factors driving the growth of this market. However, needle anxiety, emergence of oral drug delivery methods, and the growing trend of reuse of pen needles and infusion sets are the major factors restraining the growth of this market. Furthermore, increasing research and development activities and increasing diabetes-related health expenditure in emerging countries are likely to offer significant growth opportunities for players operating in the market.
The global insulin delivery devices market is segmented on the basis of type, end user, and region. In 2016, North America accounted for the largest share of the market, followed by Europe, Asia-Pacific, and RoW. The Asia-Pacific region is projected to have the highest growth rate in the forecast period. Factors such as rising prevalence of diabetes, high adoption of insulin pens, and government initiatives in Singapore are expected to support the growth of the Asia-Pacific insulin delivery devices market.
The market witnesses high competitive intensity, as there are several big and many small firms with similar product offerings. These companies adopt various strategies (product launches, collaborations, agreements, partnerships, alliances, grants, joint ventures, acquisitions, and expansions) to increase their market shares and establish a strong foothold in the global market.
In-depth interviews were conducted with CEOs, Sales and Marketing Directors, other innovation and technology directors, and executives from various key organizations operating in the insulin delivery devices market.
By Company Type: Tier 1: 70%, Tier 2: 22%, Tier 3: 8%
By Designation: Director Level: 65%, C-level: 25%, Others: 10%
By Region: North America: 55%, Europe: 20%, APAC: 20%, RoW: 5%
Key players in the global insulin delivery devices market include Becton, Dickinson and Company (U.S.), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Medtronic plc (Ireland), Animas Corporation (U.S.), Tandem Diabetes Care, Inc. (U.S.), Sanofi (France), Biocon Ltd. (India), Eli Lilly and Company (U.S.), and Insulet Corporation (U.S.).
?
Research Coverage:
This report studies the insulin delivery devices market based on type, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends, prospects, and contributions to the total market. The report forecasts the revenue of the market segments with respect to four main regions.
Reasons to Buy the Report:
The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn helps firms to garner a greater market share. Firms purchasing the report could use any one, or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.
The report provides insights on the following pointers:
‧ Market Penetration: Comprehensive information on the types of insulin delivery devices offered by top players in the insulin delivery devices market
‧ Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the insulin delivery devices market
‧ Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for insulin delivery devices across regions
‧ Market Diversification: Exhaustive information about new products, untapped regions, recent developments, and investments in the insulin delivery devices market
‧ Competitive Assessment: In-depth assessment of market shares, strategies, products, and distribution networks of the leading players in the insulin delivery devices market
TABLE OF CONTENTS
1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 16
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 RESEARCH METHODOLOGY STEPS 18
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 19
2.2.1 SECONDARY RESEARCH 19
2.2.1.1 Key data from secondary sources 19
2.2.2 PRIMARY RESEARCH 20
2.2.2.1 Key data from primary sources 21
2.2.2.2 Key insights from primary sources 21
2.2.2.3 Key industry insights 22
2.3 MARKET SIZE ESTIMATION METHODOLOGY 22
2.4 MARKET DATA VALIDATION AND TRIANGULATION 25
2.5 ASSUMPTIONS FOR THE STUDY 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 30
4.1 INSULIN DELIVERY DEVICES: MARKET SNAPSHOT 30
4.2 GEOGRAPHIC ANALYSIS: INSULIN DELIVERY DEVICES MARKET, BY TYPE (2016) 31
4.3 INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2016 VS. 2021 (USD BILLION) 32
4.4 GEOGRAPHIC SNAPSHOT OF THE INSULIN DELIVERY DEVICES MARKET 32
5 MARKET OVERVIEW 33
5.1 INTRODUCTION 34
5.2 MARKET DYNAMICS 34
5.2.1 DRIVERS 35
5.2.1.1 Growing diabetic population 35
5.2.1.2 Technological advancements in insulin delivery devices 36
5.2.1.3 Favorable reimbursement environment and government support in selected countries 37
5.2.1.4 Conferences, Meetings, and Congresses to create awareness about Insulin delivery devices 37
5.2.2 RESTRAINTS 39
5.2.2.1 Poor reimbursement structure in developing countries 39
5.2.2.2 Needle anxiety in patients to affect the growth of the pen needles and syringes market 39
5.2.2.3 Oral insulin as an alternative drug delivery method 39
5.2.2.4 Issues associated with the reuse of pen needles and infusion sets 40
5.2.3 OPPORTUNITIES 40
5.2.3.1 Increasing research and development activities 40
5.2.3.2 Increasing diabetes-related health expenditure in emerging economies 40
5.2.3.3 Safety needles 41
5.2.4 CHALLENGE 41
5.2.4.1 Severe shortage of endocrinologists in the U.S. 41
6 INSULIN DELIVERY DEVICES MARKET, BY TYPE 42
6.1 INTRODUCTION 43
6.2 PENS 44
6.2.1 REUSABLE INSULIN PENS 46
6.2.2 DISPOSABLE INSULIN PENS 47
6.3 INSULIN PUMPS 49
6.3.1 EXTERNAL/TETHERED PUMPS 50
6.3.2 PATCH PUMPS 52
6.4 PEN NEEDLES 53
6.4.1 STANDARD PEN NEEDLES 54
6.4.2 SAFETY PEN NEEDLES 55
6.5 INSULIN SYRINGES 57
6.6 OTHER INSULIN DELIVERY DEVICES 58
7 INSULIN DELIVERY DEVICES MARKET, BY END USER 60
7.1 INTRODUCTION 61
7.2 PATIENTS/HOMECARE 62
7.3 HOSPITALS & CLINICS 63
8 INSULIN DELIVERY DEVICES MARKET, BY REGION 65
8.1 INTRODUCTION 66
8.2 NORTH AMERICA 67
8.2.1 U.S. 70
8.2.1.1 Rising prevalence of diabetes and favorable reimbursement scenario 70
8.2.1.2 Awareness activities to stimulate usage of insulin delivery devices in the U.S. 70
8.2.1.3 Growing venture capital investments and issuance of IPOs 71
8.2.1.4 FDA approvals to increase the commercial availability of insulin delivery devices 71
8.2.2 CANADA 74
8.2.2.1 High prevalence of diabetes and favorable reimbursement for insulin delivery devices 74
8.2.2.2 Regulations for the usage of safety-engineered needles 74
8.3 EUROPE 77
8.3.1.1 EU’s directive on the prevention of sharps injuries in hospitals and the healthcare sector 78
8.3.2 GERMANY 81
8.3.2.1 High prevalence of diabetes, favorable reimbursement for insulin devices 81
8.3.3 FRANCE 83
8.3.3.1 High insurance coverage and increasing affordability 83
8.3.3.2 Conferences and exhibitions 83
8.3.4 U.K. 85
8.3.4.1 Role of diabetes U.K. in research and diabetes care 85
8.3.4.2 Low insulin pump penetration in the U.K. 86
8.3.5 REST OF EUROPE (ROE) 88
8.3.5.1 Spain: Regulations for mandatory use of safety needles, large diabetic population 88
8.3.5.2 Italy: Regional variations in terms of coverage and benefits to hinder market growth 89
8.3.5.3 Strong presence of major insulin delivery device manufacturers in ROE countries 89
8.3.5.4 Large diabetic populations in Russia, Romania, Poland, and Portugal 90
8.4 ASIA- PACIFIC 93
8.4.1.1 High diabetes incidence and population in Asia-Pacific 94
8.4.1.2 Partnerships among global and local players in Asia-Pacific 94
8.4.1.3 Japan: High adoption of insulin pens and approval of injectable insulin 95
8.4.1.4 India: Low penetration of pen needles & pumps and low awareness to restrain market growth 95
8.4.1.5 Government initiatives in Singapore 95
8.4.1.6 Vietnam, a potential market for insulin delivery devices 96
8.4.1.7 Australia: Amendments in NDSS to broaden patient access to diabetes products 96
8.5 ROW 99
8.5.1.1 Increasing diabetic population 100
8.5.1.2 Rising awareness on diabetes 100
8.5.1.3 Conferences 100
?
9 COMPETITIVE LANDSCAPE 103
9.1 OVERVIEW 103
9.2 MARKET SHARE ANALYSIS 104
9.3 COMPETITIVE SITUATION AND TRENDS 109
9.3.1 MARKETING AND PROMOTION 110
9.3.2 AGREEMENTS, ALLIANCES, PARTNERSHIPS, JOINT VENTURES, AND COLLABORATIONS 110
9.3.3 PRODUCT LAUNCHES 111
9.3.4 EXPANSIONS 112
9.3.5 OTHER STRATEGIES 113
10 COMPANY PROFILES 114
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
10.1 INTRODUCTION 114
10.2 BECTON, DICKINSON AND COMPANY 115
10.3 NOVO NORDISK A/S 118
10.4 MEDTRONIC PLC 120
10.5 SANOFI 122
10.6 ELI LILLY AND COMPANY 124
10.7 YPSOMED HOLDING AG 126
10.8 ANIMAS CORPORATION (JOHNSON AND JOHNSON) 128
10.9 TANDEM DIABETES CARE, INC. 130
10.10 INSULET CORPORATION 132
10.11 BIOCON LIMITED 134
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
11 APPENDIX 136
11.1 DISCUSSION GUIDE 136
11.2 OTHER DEVELOPMENTS 141
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 144
11.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 146
11.5 AVAILABLE CUSTOMIZATIONS 147
11.6 RELATED REPORTS 148
11.7 AUTHOR DETAILS 149
1 INTRODUCTION 15
1.1 OBJECTIVES OF THE STUDY 15
1.2 MARKET DEFINITION 15
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 16
1.3.2 YEARS CONSIDERED FOR THE STUDY 16
1.4 CURRENCY 17
1.5 LIMITATIONS 17
1.6 STAKEHOLDERS 17
2 RESEARCH METHODOLOGY 18
2.1 RESEARCH METHODOLOGY STEPS 18
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY 19
2.2.1 SECONDARY RESEARCH 19
2.2.1.1 Key data from secondary sources 19
2.2.2 PRIMARY RESEARCH 20
2.2.2.1 Key data from primary sources 21
2.2.2.2 Key insights from primary sources 21
2.2.2.3 Key industry insights 22
2.3 MARKET SIZE ESTIMATION METHODOLOGY 22
2.4 MARKET DATA VALIDATION AND TRIANGULATION 25
2.5 ASSUMPTIONS FOR THE STUDY 26
3 EXECUTIVE SUMMARY 27
4 PREMIUM INSIGHTS 30
4.1 INSULIN DELIVERY DEVICES: MARKET SNAPSHOT 30
4.2 GEOGRAPHIC ANALYSIS: INSULIN DELIVERY DEVICES MARKET, BY TYPE (2016) 31
4.3 INSULIN DELIVERY DEVICES MARKET SIZE, BY END USER, 2016 VS. 2021 (USD BILLION) 32
4.4 GEOGRAPHIC SNAPSHOT OF THE INSULIN DELIVERY DEVICES MARKET 32
5 MARKET OVERVIEW 33
5.1 INTRODUCTION 34
5.2 MARKET DYNAMICS 34
5.2.1 DRIVERS 35
5.2.1.1 Growing diabetic population 35
5.2.1.2 Technological advancements in insulin delivery devices 36
5.2.1.3 Favorable reimbursement environment and government support in selected countries 37
5.2.1.4 Conferences, Meetings, and Congresses to create awareness about Insulin delivery devices 37
5.2.2 RESTRAINTS 39
5.2.2.1 Poor reimbursement structure in developing countries 39
5.2.2.2 Needle anxiety in patients to affect the growth of the pen needles and syringes market 39
5.2.2.3 Oral insulin as an alternative drug delivery method 39
5.2.2.4 Issues associated with the reuse of pen needles and infusion sets 40
5.2.3 OPPORTUNITIES 40
5.2.3.1 Increasing research and development activities 40
5.2.3.2 Increasing diabetes-related health expenditure in emerging economies 40
5.2.3.3 Safety needles 41
5.2.4 CHALLENGE 41
5.2.4.1 Severe shortage of endocrinologists in the U.S. 41
6 INSULIN DELIVERY DEVICES MARKET, BY TYPE 42
6.1 INTRODUCTION 43
6.2 PENS 44
6.2.1 REUSABLE INSULIN PENS 46
6.2.2 DISPOSABLE INSULIN PENS 47
6.3 INSULIN PUMPS 49
6.3.1 EXTERNAL/TETHERED PUMPS 50
6.3.2 PATCH PUMPS 52
6.4 PEN NEEDLES 53
6.4.1 STANDARD PEN NEEDLES 54
6.4.2 SAFETY PEN NEEDLES 55
6.5 INSULIN SYRINGES 57
6.6 OTHER INSULIN DELIVERY DEVICES 58
7 INSULIN DELIVERY DEVICES MARKET, BY END USER 60
7.1 INTRODUCTION 61
7.2 PATIENTS/HOMECARE 62
7.3 HOSPITALS & CLINICS 63
8 INSULIN DELIVERY DEVICES MARKET, BY REGION 65
8.1 INTRODUCTION 66
8.2 NORTH AMERICA 67
8.2.1 U.S. 70
8.2.1.1 Rising prevalence of diabetes and favorable reimbursement scenario 70
8.2.1.2 Awareness activities to stimulate usage of insulin delivery devices in the U.S. 70
8.2.1.3 Growing venture capital investments and issuance of IPOs 71
8.2.1.4 FDA approvals to increase the commercial availability of insulin delivery devices 71
8.2.2 CANADA 74
8.2.2.1 High prevalence of diabetes and favorable reimbursement for insulin delivery devices 74
8.2.2.2 Regulations for the usage of safety-engineered needles 74
8.3 EUROPE 77
8.3.1.1 EU’s directive on the prevention of sharps injuries in hospitals and the healthcare sector 78
8.3.2 GERMANY 81
8.3.2.1 High prevalence of diabetes, favorable reimbursement for insulin devices 81
8.3.3 FRANCE 83
8.3.3.1 High insurance coverage and increasing affordability 83
8.3.3.2 Conferences and exhibitions 83
8.3.4 U.K. 85
8.3.4.1 Role of diabetes U.K. in research and diabetes care 85
8.3.4.2 Low insulin pump penetration in the U.K. 86
8.3.5 REST OF EUROPE (ROE) 88
8.3.5.1 Spain: Regulations for mandatory use of safety needles, large diabetic population 88
8.3.5.2 Italy: Regional variations in terms of coverage and benefits to hinder market growth 89
8.3.5.3 Strong presence of major insulin delivery device manufacturers in ROE countries 89
8.3.5.4 Large diabetic populations in Russia, Romania, Poland, and Portugal 90
8.4 ASIA- PACIFIC 93
8.4.1.1 High diabetes incidence and population in Asia-Pacific 94
8.4.1.2 Partnerships among global and local players in Asia-Pacific 94
8.4.1.3 Japan: High adoption of insulin pens and approval of injectable insulin 95
8.4.1.4 India: Low penetration of pen needles & pumps and low awareness to restrain market growth 95
8.4.1.5 Government initiatives in Singapore 95
8.4.1.6 Vietnam, a potential market for insulin delivery devices 96
8.4.1.7 Australia: Amendments in NDSS to broaden patient access to diabetes products 96
8.5 ROW 99
8.5.1.1 Increasing diabetic population 100
8.5.1.2 Rising awareness on diabetes 100
8.5.1.3 Conferences 100
?
9 COMPETITIVE LANDSCAPE 103
9.1 OVERVIEW 103
9.2 MARKET SHARE ANALYSIS 104
9.3 COMPETITIVE SITUATION AND TRENDS 109
9.3.1 MARKETING AND PROMOTION 110
9.3.2 AGREEMENTS, ALLIANCES, PARTNERSHIPS, JOINT VENTURES, AND COLLABORATIONS 110
9.3.3 PRODUCT LAUNCHES 111
9.3.4 EXPANSIONS 112
9.3.5 OTHER STRATEGIES 113
10 COMPANY PROFILES 114
(Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*
10.1 INTRODUCTION 114
10.2 BECTON, DICKINSON AND COMPANY 115
10.3 NOVO NORDISK A/S 118
10.4 MEDTRONIC PLC 120
10.5 SANOFI 122
10.6 ELI LILLY AND COMPANY 124
10.7 YPSOMED HOLDING AG 126
10.8 ANIMAS CORPORATION (JOHNSON AND JOHNSON) 128
10.9 TANDEM DIABETES CARE, INC. 130
10.10 INSULET CORPORATION 132
10.11 BIOCON LIMITED 134
*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.
11 APPENDIX 136
11.1 DISCUSSION GUIDE 136
11.2 OTHER DEVELOPMENTS 141
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 144
11.4 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE 146
11.5 AVAILABLE CUSTOMIZATIONS 147
11.6 RELATED REPORTS 148
11.7 AUTHOR DETAILS 149
